{"id":"xr-b-sublocadetm","safety":{"commonSideEffects":[{"rate":"~30-40","effect":"Injection site reactions (pain, erythema, induration)"},{"rate":"~10-15","effect":"Headache"},{"rate":"~10-15","effect":"Constipation"},{"rate":"~5-10","effect":"Nausea"},{"rate":"~5-10","effect":"Hyperhidrosis"},{"rate":"~5","effect":"Opioid withdrawal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SUBLOCADE delivers buprenorphine, a partial mu-opioid receptor agonist, via a subdermal implant that releases the drug over approximately one month. This sustained-release formulation reduces withdrawal symptoms and cravings in patients with opioid use disorder while minimizing the abuse potential associated with daily dosing. The extended-release mechanism improves medication adherence and reduces the burden of daily clinic visits.","oneSentence":"SUBLOCADE is a monthly subcutaneous injection of buprenorphine that provides sustained opioid agonist therapy for opioid use disorder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:28.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder in patients who have achieved and sustained clinical stability on a transmucosal buprenorphine-containing product for a minimum of 7 days"}]},"trialDetails":[{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SUBLOCADE TM"],"phase":"marketed","status":"active","brandName":"XR-B (SUBLOCADETM)","genericName":"XR-B (SUBLOCADETM)","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SUBLOCADE is a monthly subcutaneous injection of buprenorphine that provides sustained opioid agonist therapy for opioid use disorder. Used for Opioid use disorder in patients who have achieved and sustained clinical stability on a transmucosal buprenorphine-containing product for a minimum of 7 days.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}